JPM26: Sanofi’s CEO Keen To Buy the Dip as Vaccine Rhetoric Impacts Short-Term Sales
Sanofi’s CEO Paul Hudson said the firm will acquire Dynavax for $2.2 billion, targeting its adult hepatitis B vaccine Heplisav‑B, as vaccine sentiment wanes under U.S. political rhetoric. Legacy vaccine sales fell 8 % in Q3 2025, prompting a long‑term focus on adult‑focused products and further M&A, including the earlier $1.6 billion Vicebio deal. Hudson highlighted a forthcoming flu‑COVID combo shot, slated for regulatory review in 2027‑28, aimed at the over‑55/65 market. He warned short‑term volatility but sees fewer competitors willing to act now.
CRISPR–Cas3 Genome-Editing System Holds Therapeutic Potential
Researchers at the University of Tokyo demonstrated that the CRISPR‑Cas3 system can permanently suppress transthyretin (TTR) production in a mouse model of hereditary amyloidosis. Using lipid‑nanoparticle delivery, they achieved roughly 48% editing of hepatic TTR alleles and an 80% reduction...
Thoughts on Aging as Damage versus Aging as a Program of Altered Gene Expression
The article contrasts two dominant aging paradigms—damage accumulation and programmed gene‑expression—and highlights a growing synthesis of the two. It explains that a damage view drives research toward repair mechanisms, while a program view pushes gene‑expression and metabolic re‑engineering. Recent discoveries,...
Dycem, a contamination‑control specialist, celebrates 60 years since its 1966 founding, tracing roots to a high‑friction polymer discovered in 1960. The company grew from niche non‑slip products to global cleanroom solutions, now present in more than 50 countries and 30,000...
Nonlinear X-Ray Four-Photon Interaction Unveiled
Researchers have reported the first experimental observation of a nonlinear X‑ray four‑photon interaction, a phenomenon previously confined to theoretical models. The breakthrough was achieved using ultra‑intense pulses from a free‑electron laser, enabling simultaneous absorption of four X‑ray photons in a...
Jazz Sells Priority Review Voucher for $200M, Scoring Highest Price in a Decade
Jazz Pharmaceuticals announced the sale of a priority review voucher to an undisclosed buyer for $200 million, marking the highest price paid for such a voucher in a decade. The voucher, originally granted for developing a treatment for a neglected disease,...
Health Tech Funding Rounds Get Bigger when Andreessen Horowitz and General Catalyst Join
Rock Health’s latest report shows a handful of venture firms dominate health‑tech financing. When Andreessen Horowitz and General Catalyst join a round, the deal size expands dramatically, with average rounds climbing from roughly $30 million to $50 million. Together these two firms...
Novo CEO Targets Obesity Drug Acquisition to Boost Leadership
$NVO CEO Mike Doustdar was our guest on this week's live taping of the Readout LOUD. And yes, he spoke fairly plainly about his ambition to acquire another developer of obesity drugs. $5B - $20B doesn't matter, it's more about...
Program Harnesses the Power of Mentorship for Patient Organization Leaders
The Milken Institute’s FasterCures LeadersLink program, launched in 2020, provides mentorship, peer learning, and capstone projects for emerging leaders of patient advocacy organizations that fund or conduct biomedical research. The cohort‑based model connects mentees with seasoned executives, fostering strategic reflection...
A CRISPR Fingerprint of Pathogenic C. Auris Fungi for Precision Diagnostics
Researchers at Harvard’s Wyss Institute have unveiled dSHERLOCK, a digital CRISPR‑based diagnostic that can detect and quantify Candida auris from swab samples in under 40 minutes while simultaneously identifying antifungal resistance mutations. The platform merges SHERLOCK’s single‑nucleotide precision with single‑molecule...
Natural Fiber Welding Receives Investment From Provest Equity Partners and CTW Venture Partners
Natural Fiber Welding, a Peoria‑based developer of plant‑derived performance materials, secured a strategic investment from Provest Equity Partners and CTW Venture Partners. The undisclosed capital infusion coincides with Suhas Uppalapati joining the board as Chairman. The company will deploy the...
Low SIRT1 and Cholesterol Link Depression; NAD⁺ May Help
New mouse study shows cortisol, inflammation, and low SIRT1 activity all lead to depression caused by reduced neuronal cholesterol. Could statins exacerbate? And since SIRT1 is NAD⁺-dependent, could NAD⁺ boosting help treat depression?
JPM26: Gilead Captures Sunny JPM Mood With Yeztugo Numbers, HIV Vibes
Gilead’s new HIV therapy Yeztugo is gaining rapid market traction, achieving 85% payer coverage six months after its June 2025 approval and hitting the $150 million revenue target for the year. CEO Daniel O’Day highlighted voluntary licensing of the drug’s active ingredient,...
2026 Outlook: ‘Slow-Moving Catastrophe’ at FDA
The FDA is entering a ‘slow‑moving catastrophe’ as staffing cuts, politicization, and the erosion of scientific expertise undermine its regulatory capacity. Senior leadership turnover and a hiring freeze have reduced review staff by roughly 15 percent, while political pressure accelerates...
Framework to Optimize Mammalian Cell Culture Media Blending
Researchers from Osaka University and Shimadzu introduced a mathematically precise workflow for chemically defined media (CDM) blending in mammalian cell culture. The three‑step process combines experimental design, cell culture testing, and regression modeling, using PCA to eliminate multicollinearity and D‑optimal...
Drugs From the Deep
Marine organisms have yielded over 40,000 natural compounds, with 13 now FDA‑approved for cancers, viral infections and chronic pain. The primary obstacle to expanding this "blue pharmaceutical" pipeline is supply, as many bioactive molecules occur in minute quantities that are...
Biologics Manufacturers Urged to Develop QC Plans Early
At an upcoming conference, French biotech consultancy INITS will urge biologics manufacturers to establish a chemistry, manufacturing and controls (CMC) management strategy for reference materials early in development. Regulators increasingly demand deep characterization of reference material, especially by Phase III, and...
Regulatory Support Helping Biopharma to Embrace Platform Technologies
Biopharma firms are increasingly adopting platform technologies—standardized manufacturing bases that can be customized with disease‑specific modules—to accelerate product development and cut costs. Experts cite the lipid nanoparticle system used for mRNA vaccines as a prime example, where swapping the mRNA...
Pharmacovigilance Awareness Among Saudi Healthcare Students
A recent cross‑sectional study surveyed 500 Saudi pharmacy and medical students to gauge their understanding of pharmacovigilance (PV). Only 35% demonstrated sufficient knowledge of adverse drug reaction (ADR) reporting, revealing significant curriculum gaps. The researchers recommend integrating mandatory PV modules...
Intermittent Hypobaric Pressure Fights Aging and Osteoporosis
A recent preclinical study demonstrates that intermittent hypobaric pressure (IHP) exposure can mitigate age‑related bone loss and reverse cellular aging markers. Mice subjected to 2‑hour hypobaric cycles three times a week showed a 12% increase in bone mineral density and...
ImmunityBio's Anktiva Lung Cancer Data; Glaukos' Glaucoma Implant Sales Disappoint
ImmunityBio announced that its lymphocyte‑stimulating agent Anktiva, combined with checkpoint inhibitors, restored immune cells and produced objective responses in a non‑small‑cell lung cancer (NSCLC) study. The data suggest the combination could enhance the efficacy of existing immunotherapies. Meanwhile, Glaukos reported...
CGM‑based AI Outperforms HbA1c in Predicting Diabetes, Heart
Continuous glucose monitoring sensor data, with a foundation model, predicts risk of Type 2 diabetes and cardiovascular outcomes better than HbA1c New @Nature @segal_eran @WeizmannScience @GLutsker "66% of incident diabetes cases and 69% of cardiovascular deaths occurred in the top risk...
First-Time Use of AI for Genetic Circuit Design Demonstrated in a Human Cell Line
Rice University researchers unveiled CLASSIC, a high‑throughput platform that couples long‑ and short‑read sequencing to generate millions of genetic‑circuit designs in human cells. By pairing this massive library with machine‑learning models, the team demonstrated the first AI‑driven design of functional...
Thermo Fisher to Lay Off 421 Workers as It Winds Down Lab Product Site in North Carolina
Thermo Fisher Scientific announced it will phase out operations at its laboratory products facility in Asheville, North Carolina, laying off 421 workers. The shutdown is slated to be completed by the end of 2026, ending the site’s production of consumables...
Spaceflight Triggers Temporary Epigenetic Aging, Then Reversal
Space could be a testing ground for age reversal elonmusk. In 4 astronauts, epigenetic age of blood cells rose ~2 yrs by day 7 of orbit & returned to normal (or even younger) upon return 🚀 🌎 mason_lab @davefurman onlinelibrary.wiley.com/doi/10.1111/acel.70360
Undervalued $TENX Holds Promising 2026 Catalyst
I’ve gotten a lot of messages asking about my BioPick selection for this year, $TENX. I’ve responded to a few but don’t have the time to respond to everyone. I actually considered making $TENX an official “pitch”, but I don’t...
Hydrogel Cilia Set New Standard in Microrobotics
Scientists at the Max Planck Institute, HKUST and Koç University have created 18 µm hydrogel cilia that beat at 5‑40 Hz when driven by a 1.5 V electric field. Using two‑photon polymerization, they printed arrays of hundreds of these microactuators on a flexible substrate...
Genetically Informed ALS Therapies Extend Beyond Mutation‑Specific Targets
Nice ALS market map 👇 When precision approaches go broad….looks like yes that can happen. “…a third category being overlooked: 28 programs that are genetically informed but not mutation-restricted. Examples: drugs targeting TDP-43 protein clumps or repeat RNA toxicity. These mechanisms...
Saudi FDA Approves IBRX Despite Flawed, Inconclusive Data
The Saudi FDA approved $IBRX Anktiva in lung cancer based on a discontinued randomized study with inconclusive post-hoc data + a non-randomized study with a made-up nonsense responder analysis. These are the data that @DrPatrick and $IBRX tried to submit...
The AbbVie Strategy, a Company at an Inflection Point
AbbVie’s historic reliance on Humira has been upended by a 54.5% U.S. revenue drop as biosimilars entered in 2023, prompting a strategic pivot toward its next‑generation immunology drugs Skyrizi and Rinvoq. The company projects combined revenue of over $31 billion from...
Decade‑Old Myths Still Fuel JPM Healthcare Talk
A dozen years old, but curious how many of these little lies are still told around the #JPM26 conference.... "Top 10 Little White Lies Told At The JP Morgan Healthcare Conference" https://t.co/0er4Beffn3
AI Boosts Individual Impact, Shrinks Collective Research Breadth
How has AI impacted science? Analysis of >41m papers. A paradox: Expansion of individual's impact but contraction in breadth of topics researched collectively https://t.co/npovh0eSL8 https://t.co/iMY3cEd9LE https://t.co/iErtpnuJQR
FDA Seeks Changes to GLP-1, Flu Shot Labels
The FDA has asked manufacturers of GLP‑1 weight‑loss drugs, including Wegovy, Saxenda and Zepbound, to drop the suicide‑ideation warning after a comprehensive safety review found no elevated risk. The agency’s meta‑analysis of 91 trials involving more than 100,000 participants confirmed...
Invisible Immune Deficits Make Low‑risk Infections Deadly
Why do so many apparently healthy people die or get severely ill from infections that would be considered low risk? For one, we don't have any way of assessing a person's immune system function in the clinic https://t.co/CshtAxDep9 https://t.co/uk5nDnyjnr
Weakened Vaccine Policy Threatens Kids, Monitoring Becomes Opaque
Dismantling US vaccination policy will lead to more vaccine-preventable disease in kids. But how easy will it be to monitor the impact of the erosion of vaccine coverage? New data collection rule changes raise serious concerns about how visible results...
AstraZeneca’s Path to $80B by 2030 Paved With ADCs, Cell Therapies, Near-Term Product Launches
At the J.P. Morgan Healthcare Conference, AstraZeneca reaffirmed its ambition to generate $80 billion in revenue by 2030, a target now seen as attainable. The company highlighted three near‑term product launches—baxdrostat for hypertension, camizestrant for breast cancer, and gefurulimab for myasthenia...
44‑Metabolite Signature Improves Prediction of Diabetes Progression
There are about 100m Americans with pre-diabetes. But who will progress? Enhanced risk prediction of Type 2 diabetes from a 44 -metabolite signature @NatureMedicine https://t.co/UxmQaD88s4 https://t.co/jhmP3enyTa
Using Claude Code Wrong? Real Genomics Workflow Works
1/ Bioinformaticians get mediocre results with Claude Code and blame the tool. You are doing it wrong. Here's what actually works for genomics analysis: https://t.co/GDOq7SPzla
Super-Resolution Ultrasound Reveals Brain Issues in Parkinson’s
A new super‑resolution ultrasound technique can visualize microvascular abnormalities in the brains of Parkinson's patients with unprecedented clarity. In a study of 120 early‑stage participants, the method identified vascular biomarkers up to five years before clinical symptoms appeared. The non‑invasive...
Hippocratic AI Builds in Life Sciences with Grove AI Buy
Hippocratic AI announced the acquisition of Grove AI, a pharma‑R&D specialist, and launched a dedicated life‑sciences division headed by Dr Ahad Wahid. The move adds the Grace agent, which automates clinical‑trial tasks, to Hippocratic's safety‑first generative AI portfolio. The company,...
#JPM26: Day 3 at the JP Morgan Healthcare Conference
Day three of the JPMorgan Healthcare Conference saw sessions winding down as investors turned their attention to key presentations, notably from Chinese contract research giant WuXi AppTec. The company used its slot to unveil a refreshed drug‑development platform and hint...
#JPM26: Q&A with Bristol Myers Squibb CEO Chris Boerner on 2026 Outlook
Chris Boerner, in his third year as Bristol Myers Squibb CEO, opened the JPMorgan Healthcare Conference with a forward‑looking Q&A on the company’s 2026 outlook. He outlined a $45 billion revenue target, driven by late‑stage oncology and immunology assets, while emphasizing...
Mechanotransduction via Piezo1 Drives the Benefits of Exercise on Bone Tissue
Researchers identified the mechanosensitive ion channel Piezo1 in bone‑marrow mesenchymal stem cells as the key mediator of exercise‑induced bone health. Mechanical loading activates Piezo1, which suppresses marrow adipogenesis, curtails a Ccl2‑Lcn2 inflammatory loop, and promotes osteoblast differentiation. Mice lacking Piezo1...
Common Changes in RNA Splicing and Processing with Age Across Tissues
Researchers applied differential network analysis to human transcriptomes (ages 20‑70) across multiple tissues, uncovering age‑related transcriptional changes that standard differential expression missed. By integrating both methods, they identified a core set of genes consistently modulated with age, heavily enriched for...
Phase 3 Data More Reliable; P2 Placebos Often Variable
Another reason a P3 study can fail while a P2 was successful is that P2 placebo groups, with narrower eligibility criteria & fewer patients, often have more variable placebo-adjusted effects Use Phase 3 data, often on drug labels, to make comparisons;...
JPM: Illumina Launches 'Unprecedented' Disease Biology Atlas
Illumina unveiled the Billion Cell Atlas, a genome‑wide perturbation database that profiles 20,000 genes across 250 disease‑relevant human cell types using CRISPR. The initial release contains data from 150 million cells and aims to expand to five billion cells within three years,...
AstraZeneca Bets on In-House AI to Speed up Oncology Research
AstraZeneca is acquiring Boston‑based Modella AI to bring its pathology‑focused models, data, and talent directly into the company’s oncology research pipeline. The move shifts the relationship from a collaborative partnership to full ownership, aiming to embed AI in quantitative pathology,...
UK Names Health Data Chief, as BIA Finds Its New CEO
Former Moderna executive Dr Melanie Ivarsson has been named chief executive of the UK Health Data Research Service, a £600 million government‑backed unit that will create a secure, single gateway to NHS health data. The HDRS, based at the Wellcome Genome...
Antimicrobial Polymer Nanocomposites Made with Beetroot
A study in *Materials* shows that copper nanoparticles produced via a beetroot‑based green synthesis exhibit markedly stronger antimicrobial activity when embedded in polypropylene than both silver‑based composites and chemically reduced copper. The green‑synthesized copper particles are smaller, less prone to...
New Drug Candidate Reverses Metabolic Liver Disease and Fibrosis
Researchers at McMaster University, in partnership with Espervita Therapeutics, reported preclinical data showing that the small‑molecule EVT0185 can both prevent and reverse liver fibrosis in mouse models of metabolic dysfunction‑associated steatohepatitis (MASH). The compound simultaneously inhibits the enzymes ACLY and...